Interaktionen der Protonenpumpenhemmer mit oralen Bisphosphonaten und Frakturrisiko

Wird die enterale Aufnahme von Bisphosphonaten durch den Anstieg des Magen-pH-Wertes, z. B. durch Protonenpumpenhemmer, beeinträchtigt?

• Literatur

• 1 Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med 2011; 13: 998-1004
• 2 Bartl R, Frisch B, von Tresckow E, Bartl C. Bisphosphonates in Medical Practice. Heidelberg: Springer; 2007
• 3 deVries F, Cooper A, Cockle S et al. Fracture risk in patients receiving acid-suppressant medications alone and in combination with bisphosphonates. Osteoporos Int 2009; 20: 1989-1998
• 4 Gray S, LaCroix A, Larson J et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s health initiative. Arch Intern Med 2010; 170: 765-771
• 5 McGowan B, Bennett K, Barry M. Prescribing of anti-osteoporotic therapies following the use of proton pump inhibitors in general practice. Pharmacoepidemiol Drug Saf 2010; 19: 763-769
• 6 Roux C, Goldstein J, Zhou X et al. Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors. Osteoporos Int 2012; 23: 227-284
• 7 Targownik L, Lix L, Metge C et al. Verwendung von Protonenpumpenhemmern und das Risiko von Osteoporose-bedingten Frakturen. CMAJ 2011; 4: 319-326
• 8 Targownik L, Lix L, Leung S et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010; 138: 896-904
• 9 Yang Y, Lewis J, Epstein S et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-2953